PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Sep 18, 2019
SOUTH PLAINFIELD, N.J. , Sept. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it has priced its private offering of $250.0 million aggregate principal amount of its convertible senior notes due 2026 (the "Notes"). The Notes will be sold only to qualified
Additional Formats
Sep 18, 2019
SOUTH PLAINFIELD, N.J. , Sept. 18, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today the pricing of a public offering of 2,475,248 shares of its common stock at a public offering price of $40.40 per share, before underwriting discounts and commissions.
Additional Formats
Sep 17, 2019
SOUTH PLAINFIELD, N.J. , Sept. 17, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing a public offering of $100.0 million of shares of its common stock. PTC intends to grant the underwriter an option for a period of 30 days to purchase up to an
Additional Formats
Sep 17, 2019
SOUTH PLAINFIELD, N.J. , Sept. 17, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing an offering of $250.0 million aggregate principal amount of its convertible senior notes due 2026 (the "Notes"), subject to market conditions and other factors.
Additional Formats
Sep 06, 2019
-Global program recognizes excellence and innovation in the Duchenne muscular dystrophy community- -28 projects awarded funding since its inception- SOUTH PLAINFIELD, N.J. , Sept. 6, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's
Additional Formats
Aug 06, 2019
-Translarna™ approved in Brazil & PTC entered first annual contract with Ministry of Health- -Emflaza® receives FDA approval for a label expansion to treat DMD patients 2-5 years of age- -PTC expands gene therapy infrastructure & portfolio- SOUTH PLAINFIELD, N.J. , Aug.
Additional Formats
Aug 05, 2019
- Facility will support gene therapy production and continued development of pipeline of investigational medicines - - PTC to gain access to highly-qualified specialists in biologics operations - SOUTH PLAINFIELD, N.J. , Aug. 5, 2019 /PRNewswire/ -- PTC Therapeutics, Inc.
Additional Formats
Jul 31, 2019
SOUTH PLAINFIELD, N.J. , July 31, 2019 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on July 26, 2019 it approved non-statutory stock options to purchase an aggregate of 208,100 shares of its common stock to 72 new employees.
Additional Formats
Jul 23, 2019
SOUTH PLAINFIELD, N.J. , July 23, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2019 financial results and provide an update on the company's business and outlook on Tuesday, August 6,
Additional Formats
Jul 01, 2019
- Collaboration expands PTC's Gene Therapy portfolio to rare ophthalmic diseases - SOUTH PLAINFIELD, N.J. and BOSTON , July 1, 2019 /PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) and Odylia Therapeutics today announced a strategic collaboration to develop novel gene therapies in rare
Additional Formats